Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
| ▸ | TTR | P02766 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27743583 | 0.89 | MAOA (0.36) | MAPTMAOAMAOBKIF11KDM4E | |
| SCHEMBL3584770 | 0.88 | ALDH1A1 (0.37) | MAPTALDH1A1L3MBTL1MAOAMAOB | |
| SCHEMBL3588701 | 0.87 | MAPT (0.37) | MAPTALDH1A1L3MBTL1KIF11KDM4E | |
| SCHEMBL3587861 | 0.85 | MAPT (0.38) | MAPTALDH1A1L3MBTL1MAOAMAOB | |
| SCHEMBL1447006 | 0.85 | MAPT (0.39) | MAPTALDH1A1KIF11KDM4EGAA | |
| SCHEMBL3585030 | 0.84 | TDP2 (0.37) | MAPTALDH1A1L3MBTL1KDM4EHPGD | |
| SCHEMBL3585249 | 0.83 | MAPT (0.38) | MAPTALDH1A1L3MBTL1MAOAMAOB | |
| SCHEMBL1447360 | 0.83 | MAPT (0.36) | MAPTALDH1A1L3MBTL1KIF11KDM4E | |
| SCHEMBL3590964 | 0.81 | ALOX5 (0.40) | MAPTALDH1A1L3MBTL1MAOAMAOB | |
| SCHEMBL1447450 | 0.81 | MAPT (0.36) | MAPTALDH1A1L3MBTL1KIF11KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9446012-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-09-20 | — | — | US | disclosed |
| US-20140024682-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & CA, S.A. (PT) | 2014-01-23 | — | — | US | disclosed |
| US-8536203-B2 | Pharmaceutical compounds | BIAL-PORTELA & CA, S.A. (PT) | 2013-09-17 | — | — | US | disclosed |
| EP-2617713-A1 | New Pharmaceutical Compounds | BIAL - Portela & Ca., S.A. (PT) | 2013-07-24 | — | — | EP | disclosed |
| US-20100168113-A1 | Pharmaceutical Compounds | BIAL-PORTELA & CA., S.A. (PT) | 2010-07-01 | — | — | US | disclosed |
| CN-101248064-A | Nitrocatechol derivatives as COMT inhibitors | PORTELA & CA SA (PT) | 2008-08-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168113-A1 | Pharmaceutical Compounds | PMP22, CNR2, OPRL1 | MAPT 310/4885ALDH1A1 1070/4885L3MBTL1 4603/4885 |
| US-20140024682-A1 | PHARMACEUTICAL COMPOUNDS | PMP22, CNR2, OPRL1 | MAPT 310/4885ALDH1A1 1070/4885L3MBTL1 4603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.